As I see it

Share this article:
Although feelings in the mainstream drug industry will be mixed, it's time to end the secrecy that surrounds the FDA's decision-making on approving drugs.

Initially legislated to protect trade secrets and then expanded by the agency itself in Nixon-era regulations to broadly protect info deemed commercial/confidential, the prohibition prevents FDA staff from even acknowledging the existence of a pending application, much less address decision-making.

Coexisting with Securities and Exchange Commission requirements that compel drug companies to disclose significant FDA preapproval review developments that could  impact stock prices, the ban at the FDA is made ridiculous and harmful by real-time realities of the Internet. For current evidence of this, read Matthew Herper's article, The FDA's Black Box in Forbes magazine, where he discusses the investor- and company-harming negatives of the FDA's rejection of 10 drugs against favorable advisory committee recommendations.

Were they duds or narrow misses? Nobody could say, objectively. In none of these cases did the sponsor release the FDA's rejection letter. 

But while they may be masters in marketing communications, few corporations have the gift of clairvoyance in foretelling how their critics and the media will manipulate their carefully crafted disclosures.

The FDA, meanwhile, is left mute by its self-inflicted prohibition. This may be how some sponsors prefer it remain, since an unmuzzled FDA would end their control of what the public knows about their future product's problems.   

Forward-thinking sponsors please step forward!

Dickinson is editor of Dickinson's FDA Webview (              
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in As I See It

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in As I See It

As I See It: Patient Centricity

As I See It: Patient Centricity

A patient who is diagnosed earlier and receives the most efficacious treatment is the least expensive

As I See It: FDA's social-media moves

As I See It: FDA's social-media moves

FDA has insisted that its antique regulations can address every new promotional challenge

As I See It: FDA and marketing materials

As I See It: FDA and marketing materials

The more clarity that FDA provides, the more confident companies can be in their medical communications